Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ICUI
stocks logo

ICUI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
542.87M
-13.8%
-0.217
-77.66%
531.70M
-11.31%
0.210
-133.33%
537.60M
-2.05%
0.335
-76.57%
Estimates Revision
The market is revising Upward the revenue expectations for ICU Medical, Inc. (ICUI) for FY2025, with the revenue forecasts being adjusted by 1.1% over the past three months. During the same period, the stock price has changed by 8.47%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.1%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-248.08%
In Past 3 Month
Stock Price
Go Up
up Image
+8.47%
In Past 3 Month
Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 172.00 USD with a low forecast of 172.00 USD and a high forecast of 172.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 172.00 USD with a low forecast of 172.00 USD and a high forecast of 172.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 142.350
sliders
Low
172.00
Averages
172.00
High
172.00
Current: 142.350
sliders
Low
172.00
Averages
172.00
High
172.00
Piper Sandler
Overweight
maintain
$153 -> $172
2025-11-07
Reason
Piper Sandler
Price Target
$153 -> $172
2025-11-07
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on ICU Medical to $172 from $153 and keeps an Overweight rating on the shares. The firm notes ICU reported Q3 results, including revenue upside across all segments, healthy margin outperformance, and a wide EPS beat. This contributed to management resetting EBITDA and EPS guidance meaningfully higher to account for the overage. Piper likes that the implied outlook for Q4 was prudently left unchanged.
KeyBanc
Overweight
maintain
$173 -> $175
2025-11-07
Reason
KeyBanc
Price Target
$173 -> $175
2025-11-07
maintain
Overweight
Reason
KeyBanc raised the firm's price target on ICU Medical to $175 from $173 on higher estimates, while keeping an Overweight rating on the shares. The firm remains encouraged by ICU's underlying operational progress as well as ability to raise 2025 EPS/EBITDA guidance, despite continued macro headwinds.
KeyBanc
Brett Fishbin
Overweight
downgrade
$191 -> $173
2025-10-21
Reason
KeyBanc
Brett Fishbin
Price Target
$191 -> $173
2025-10-21
downgrade
Overweight
Reason
KeyBanc analyst Brett Fishbin lowered the firm's price target on ICU Medical to $173 from $191 to reflect lower industry/peer multiples, while keeping an Overweight rating on the shares. The firm remains encouraged by ICU's significant progress in demonstrating increased operational and financial stability.
Piper Sandler
Jason Bednar
Overweight
maintain
$145 -> $153
2025-09-10
Reason
Piper Sandler
Jason Bednar
Price Target
$145 -> $153
2025-09-10
maintain
Overweight
Reason
Piper Sandler analyst Jason Bednar raised the firm's price target on ICU Medical to $153 from $145 and keeps an Overweight rating on the shares. One of the elements the firm liked of the ICU story when it launched coverage last month was the effects portfolio transformation could have on the business profile as it relates to the absolute financials that are reported, the growth of the asset, balance sheet leverage, and the investability of shares. The JV that deconsolidated the IV Solutions business from the ICU P&L was a major step forward, but Piper is saying today it strongly believes it's just the first step as the firm thinks ICU management may be moving forward with evaluating options for remaining pieces of the company's Vital Care portfolio, and that it's the completion of the JV just a few months ago that allows management to focus more attention on finding the best value-creating transaction for the Vital Care pieces.
Piper Sandler
Overweight
initiated
$145
2025-08-15
Reason
Piper Sandler
Price Target
$145
2025-08-15
initiated
Overweight
Reason
Piper Sandler initiated coverage of ICU Medical with an Overweight rating and $145 price target.
Piper Sandler
Jason Bednar
initiated
$145
2025-08-15
Reason
Piper Sandler
Jason Bednar
Price Target
$145
2025-08-15
initiated
Reason
As previously reported, Piper Sandler analyst Jason Bednar initiated coverage of ICU Medical with an Overweight rating and $145 price target. The infusion pump market faced regulatory and quality control challenges the last few years, and ICU has borne its own internal headwinds in the wake of the Smiths Medical transaction, the firm notes. The path to stability for the industry and ICU has been uneven and taken longer to achieve than many anticipated, but Piper believes the weight of the evidence points to ICU being in the early stages of finally showing the operational improvements necessary for margins and cash flow to take steps forward. As that improvement in fundamentals plays out, the firm sees shares as likely to recapture earnings multiple at least in the upper teens.
See All Ratings

Valuation Metrics

The current forward P/E ratio for ICU Medical Inc (ICUI.O) is 178.32, compared to its 5-year average forward P/E of -21.55. For a more detailed relative valuation and DCF analysis to assess ICU Medical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-21.55
Current PE
178.32
Overvalued PE
227.26
Undervalued PE
-270.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.97
Undervalued EV/EBITDA
11.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.94
Current PS
0.00
Overvalued PS
2.72
Undervalued PS
1.16
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ICUI News & Events

Events Timeline

(ET)
2025-11-06
18:14:32
ICU Medical increases FY25 EPS forecast to $7.35-$7.65, up from $6.85-$7.15
select
2025-11-06
18:12:59
ICU Medical announces Q3 adjusted EPS of $2.03, surpassing consensus estimate of $1.43
select
2025-08-07 (ET)
2025-08-07
17:44:41
ICU Medical narrows FY25 EPS view to $6.85-$7.15 from $6.55-$7.25
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-17NASDAQ.COM
Insiders Purchase Shares of VHT ETF Holdings

  • Insider Buying in Vanguard Health Care ETF: 17.6% of the weighted holdings in the Vanguard Health Care ETF (VHT) have seen insider buying in the past six months.

  • ICU Medical Inc Activity: ICU Medical Inc (ICUI), making up 0.05% of VHT, has had two directors and officers purchase shares recently, with the ETF holding $9,411,006 worth of ICUI.

  • Tandem Diabetes Care Inc Activity: Tandem Diabetes Care Inc (TNDM), the #243 largest holding in VHT, also shows insider buying from two directors and officers, with the ETF holding $3,407,114 worth of TNDM.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.

[object Object]
Preview
6.0
11-07Benzinga
Keybanc Keeps Overweight Rating on ICU Medical and Increases Price Target to $175

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
9.5
11-07NASDAQ.COM
After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results

  • Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.

  • Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.

  • Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.

  • ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ICU Medical Inc (ICUI) stock price today?

The current price of ICUI is 142.35 USD — it has decreased -1.17 % in the last trading day.

arrow icon

What is ICU Medical Inc (ICUI)'s business?

ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.

arrow icon

What is the price predicton of ICUI Stock?

Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 172.00 USD with a low forecast of 172.00 USD and a high forecast of 172.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ICU Medical Inc (ICUI)'s revenue for the last quarter?

ICU Medical Inc revenue for the last quarter amounts to 536.99M USD, decreased -8.85 % YoY.

arrow icon

What is ICU Medical Inc (ICUI)'s earnings per share (EPS) for the last quarter?

ICU Medical Inc. EPS for the last quarter amounts to -0.14 USD, decreased -89.63 % YoY.

arrow icon

What changes have occurred in the market's expectations for ICU Medical Inc (ICUI)'s fundamentals?

The market is revising Upward the revenue expectations for ICU Medical, Inc. (ICUI) for FY2025, with the revenue forecasts being adjusted by 1.1% over the past three months. During the same period, the stock price has changed by 8.47%.
arrow icon

How many employees does ICU Medical Inc (ICUI). have?

ICU Medical Inc (ICUI) has 15000 emplpoyees as of December 05 2025.

arrow icon

What is ICU Medical Inc (ICUI) market cap?

Today ICUI has the market capitalization of 3.51B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free